New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease. The drug has been licensed for use in the UK but rejected by the NHS spending watchdog ...
The Alzheimer’s Association has set its annual Walk to End Alzheimer’s for Saturday, Oct. 26, at Trinity United Methodist ...
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news ...
In a blow to tens of thousands of Brits, draft guidance by the NHS spending watchdog ruled the benefits of the drug are far ...
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the ...
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
In the heart of Seattle, some of the world’s most brilliant minds study the brain at the Allen Institute, where researchers ...
On the frontier of some of biopharma's lucrative markets, one competitor's stumble can be a win for one of its rivals. And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road ...
Having these warning signs checked out could provide an opportunity to delay or even prevent the onset of dementia or Alzheimer's.
Right now across the country, tens of millions of older adults and people with serious disabilities have a choice to make: whether to stick with their current Medicare option, or change during Open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback